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Fibromodulin (FMOD) is an extracellular matrix (ECM) small leucine-rich proteoglycan (SLRP) that plays
an important role in cell fate determination. Previous studies revealed that not only is FMOD critical in
fetal-type scarless wound healing, but it also promotes adult wound closure and reduces scar formation.
In addition, FMOD-deﬁcient mice exhibit signiﬁcantly reduced blood vessel regeneration in granulation
tissues during wound healing. In this study, we investigated the effects of FMOD on angiogenesis, which
is an important event in wound healing as well as embryonic development and tumorigenesis. We found
that FMOD accelerated human umbilical vein endothelial HUVEC-CS cell adhesion, spreading, actin stress
ﬁber formation, and eventually tube-like structure (TLS) network establishment in vitro. On a molecular
level, by increasing expression of collagen I and III, angiopoietin (Ang)-2, and vascular endothelial growth
factor (VEGF), as well as reducing the ratio of Ang-1/Ang-2, FMOD provided a favorable network to mobi-
lize quiescent endothelial cells to an angiogenic phenotype. Moreover, we also conﬁrmed that FMOD
enhanced angiogenesis in vivo by using an in ovo chick embryo chorioallantoic membrane (CAM) assay.
Therefore, our data demonstrate that FMOD is a pro-angiogenic and suggest a potential therapeutic role
of FMOD in the treatment of conditions related to impaired angiogenesis.
 2013 The Author. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
The formation of new capillaries, aka ‘angiogenesis’, is an
important natural process required for embryonic development,
wound healing, and tumor formation [1–3]. During angiogenesis,
normally quiescent endothelial cells (ECs) are stimulated to switch
to an angiogenic phenotype, and undergo a cascade of events reg-
ulated by a diverse group of growth factors to complete vessel mat-uration [2,4,5]. Otherwise, blockage of endothelial interactions
with the extracellular matrix (ECM) inhibits neovascularization
in vivo as well as the formation of endothelial tube-like structures
(TLS) in vitro [4,6–8], which suggests ECM molecules are also crit-
ical for angiogenesis [9–12].
Fibromodulin (FMOD) is a broadly distributed ECM protein [13]
that plays an extensive role in cell fate determination, as FMOD is
an integral component for maintenance of endogenous stem cell
niches [14] and can directly reprogram somatic cells to a minimally
proliferative, multipotent progenitor state [15]. Meanwhile, FMOD
is critical for fetal-type scarless wound repair, exerts anti-scarring
effects in adult wound healing, and modulates transforming
growth factor (TGF)-b ligand and receptor expression [16–19].
Since FMOD-deﬁcient mice exhibit signiﬁcantly reduced blood ves-
sel regeneration in granulation tissues during wound healing [19],
FMOD may also be involved in angiogenesis.
To investigate the role of FMOD in angiogenesis, we ﬁrstly eval-
uated the effects of FMOD on human umbilical vein endothelial
HUVEC-CS cell TLS formation. Then, we assessed FMOD’s inﬂuence
on cell adhesion, spreading, proliferation, and gene expression.
Chick embryo chorioallantoic membrane (CAM) assay was used
to conﬁrm FMOD’s effect of angiogenesis in vivo.
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2.1. Cell culture
HUVEC-CS cells (passages 4–6; CRL-2873; ATCC, Manassas, VA)
were cultured in DMEM supplied with 20% inactivated fetal bovine
serum (FBS) and 1% penicillin/streptomycin (Life Technologies,
Grand Island, NY).
2.2. TLS formation analysis
3  104 cells/cm2 HUVEC-CS cells were seeded into 6-well
plates for 24 h before treatment with 3 ml fresh medium supplying
0, 2, 10 or 50 lg/ml recombinant human FMOD [15,19]. Media
were changed every 3 days. On day-15, cells were ﬁxed in 4%-para-
formaldehyde in phosphate buffered saline (PBS). Five images per
well, four wells per treatment were documented using an Olympus
ﬂuorescent microscope (Center Valley, PA). Images were assessed
by recording dimensional and topological analyses with Image J
(NIH, Bethesda, MD) [20]. Segment length of TLS is deﬁned as the
individual TLS length from one junction to the next. Calcium
deposits were identiﬁed by Alizarin Red (Sigma–Aldrich, St. Louis,
MO) staining [21].
2.3. Cell adhesion and spreading analysis
4-well Millicell EZ slides (EMD Millipore, Billerica, MA) were
coated with Attachment Factor (0.1% gelatin; Life Technologies)
at 37 C for 30 min. 3  104 cells/cm2 HUVEC-CS cells were seeded
with 0.5 ml fresh medium containing 0, 2, 10 or 50 lg/ml FMOD.
After 3 h (which corresponds to the time when the collagen overlay
was applied [22]), non-adhering cells were removed by a gentle
wash with ice-cold PBS. After ﬁxation, cells were stained with
mouse anti-human monoclonal antibodies against vinculin (Ab-
cam, Cambridge, CA) followed by Alexa Fluor 594-labeled anti-
mouse IgG (Life Technologies). Alexa Fluor 488-labeled phalloidin
(Life Technologies) and 40,6-diamidino-2-phenylindole (DAPI; Sig-
ma–Aldrich) were used to stain actin ﬁlaments and nuclei, respec-
tively. Six images per well, four wells per treatment were recorded
and analyzed. Vinculin and actin ﬁlaments staining were docu-
mented with a confocal laser scanning microscope (CLSM; Leica
Microsystems Inc., Buffalo Grove, IL).
2.4. Cell proliferation analysis
6  103 cells/cm2 HUVEC-CS cells were seeded into a 96-well
plate for 24 h before treatment with 200 ll fresh medium with 0,
2, 10 or 50 lg/ml FMOD. Cell proliferation was measured by Vy-
brant MTT Cell Proliferation Assay Kit (Life Technologies).
2.5. Quantitative reverse transcriptase-polymerase chain reaction
(qRT-PCR)
Cells were collected on day-5, -10, and -15 during TLS formation
assay. RNA was extracted using RNeasy Mini Kit with DNase
treatment (Qiagen, Valencia, CA) followed by reverse transcription
(RT) using iScript™ Reverse Transcription Supermix for RT-qPCR
(Bio-Rad Laboratories, Hercules, CA). qRT-PCR of pro-a1 chain of
collagen III (Col3a1; prime 1: 50-TCTTGGTCAGTCCTGTGCGGATA-
30, prime 2: 50-AACGGATCCTGAGTCACAGACA-30 [23]) and tyrosine
kinase receptors 2 (Tie2; primer 1: 50-TTGAAGTGGAGAGAAG
GTCTG-30, primer 2: 50-GTTGACTCATAGCTCGGACCAC-30 [24]) was
performed on a 7300 Real-Time PCR system (Life Technologies)
with iTaq™ Universal SYBR Green Supermix (Bio-Rad Laborato-
ries). Quantitation of other genes was accessed by using TaqManGene Expression Assays (Life Technologies) and SsoFast™ Probes
Supermix with ROX (Bio-Rad Laboratories). Concomitant GAPDH
was also performed in separate tubes for each RT reaction as
housekeeping standard. For each gene, three separate sets of
qRT-PCR analyses were performed using different cDNA templates.
2.6. CAM assay
The in ovo CAM assay was performed as previously described
[25]. Fertilized chicken eggs (Charles River Labs, North Franklin,
CT) were positioned in a horizontal position and incubated at
37 C under 60% relative humidity in an egg incubator equipped
with a turner which automatically turned eggs 6 times/day. On
day-3, 5 ml albumin was withdrawn using a syringe with a 21-
gage needle through the pointer end of the egg in order to allow
detachment of the developing CAM from the eggshell. A rectangle
window was cut in the shell as a portal of access for the CAM, and
then the eggs were returned back to the incubator. On day-10,
2.0 mg/ml FMOD mixed with 30 ll 1:3-diluted growth factor re-
duced Matrigel (BD Bioscience, Franklin Lakes, NJ) was loaded on
an autoclaved 5  5-mm polyester mesh layer (grid size:
530 lm; Component Supply Company, Fort Meade, FL), and was
incubated for 45 min at 37 C for gel formation before transplanta-
tion on the CAM. On day-13, CAMs were excised, ﬁxed, and
photographed.
2.7. Statistical analysis
Generally, data were presented as mean ± the standard error of
the mean (SEM). Statistical signiﬁcance was performed with Orig-
inPro 8 (Origin Lab Corp., Northampton, MA) including one-way
ANOVA, two-sample t-test, and Mann–Whitney analyses. A P-value
less than 0.05 was considered statistically signiﬁcant.3. Results
3.1. FMOD promoted HUVEC-CS cell TLS formation
High-density cultured HUVEC-CS cells formed a conﬂuent
monolayer with a characteristic polygonal morphology. On day-
15, several HUVEC-CS cells spontaneously sprouted and connected
with each other to form TLSs on the monolayer, as previously de-
scribed in adult bovine aorta ECs [26]. Compared to non-FMOD
controls, FMOD administration extensively enhanced HUVEC-CS
TLS formation, and induced these TLSs to establish polygon struc-
tures referred to as complex meshes (Fig. 1A), which indicates rapid
cell migration [27]. FMOD signiﬁcantly increased both dimensional
(total length of cellular TLS network per area; Fig. 1B) and topolog-
ical parameters (number of junctions, branches, and meshes per
area; Fig. 1C) of TLSs. As a result, more short (0–100 lm) and less
long (150–300 lm) individual TLSs (Fig. 1D, E) were observed in
FMOD-treated groups (Fig. 1D and E). Interestingly, FMOD pro-
moted TLS formation in a dose-dependent manner in a range of
0–10 lg/ml, while 50 lg/ml FMOD signiﬁcantly lowered both
dimensional and topological parameters of TLSs compared with
that of 10 lg/ml FMOD (Fig. 1B and C). Moreover, 50 lg/ml FMOD
also resulted in calciﬁed nodule-like cluster formation (Fig. 1A and
F).
3.2. FMOD accelerated HUVEC-CS cell attachment and spreading, but
not cellular proliferation
FMOD signiﬁcantly improved HUVEC-CS cell adhesion (Fig. 2A).
For instance, 10 lg/ml FMOD resulted in approximately 82%
(2.46  104 cell/cm2) seeded cell attachment in the ﬁrst 3 h, while
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Fig. 1. FMOD promoted HUVEC-CS TLS formation in vitro. (A) On day-15, HUVEC-CS cells spontaneously formed TLSs (outlined in the lower panel). (B) Dimensional and (C)
topological parameters of the HUVEC-CS TLS network were quantitated; N = 4. (D) Distribution of TLS segment length in FMOD-treated groups was compared to non-FMOD
(0 lg/ml FMOD) control. # and & indicated higher and lower frequency, respectively. (E) The median (center line), 25%–75% percentiles (box) and lowest and highest values
(bars) of TLS segment length were also shown and analyzed by Mann–Whiney test. (F) Alizarin Red staining demonstrated calciﬁed cluster formation in 50 lg/ml FMOD
group. Bar = 200 lm. ⁄signiﬁcant difference compared to non-FMOD control (B, C, and E).
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group during the same period. It is also worth noting that fewer
cells adhered in 50 lg/ml FMOD (2.12  104 cell/cm2) than in
10 lg/ml FMOD (Fig. 2A). Immune staining revealed only a small
amount of vinculin-positive focal adhesion and actin stress ﬁbers
in attached non-FMOD-treated cells, while vinculin staining was
co-located with actin ﬁbers (Fig. 2B). On the contrary, FMOD signif-
icantly induced vinculin expression and actin stress ﬁber formation
(Fig. 2B). Clear vinculin and actin stress ﬁber staining was observed
in 2 lg/ml FMOD-treated cells (Fig 2B). In 10 lg/ml FMOD-treated
cells, vinculin was intensively expressed and organized as special
network throughout the cell body. Phalloidin staining also evi-
denced an abundant number of actin stress ﬁbers in the cytoplasm
as well as cell edge, suggesting cellular spreading and migration(Fig. 2B). Interestingly, 50 lg/ml FMOD-treated cells aggregated
to form cellular clusters surrounded by aggregated vinculin and ac-
tin stress ﬁbers (Fig. 2B). Cells were signiﬁcantly more spread out
when treated with 2 and 10 lg/ml FMOD compared to non-FMOD
treatment (Fig. 2C). However, 50 lg/ml FMOD-treated cells
adopted a ‘‘rounder’’ morphology in cell cluster (Fig. 2B).
Meanwhile, in order to exclude the possibility that the inducing
effect of FMOD on HUVEC-CS cell TLS formation was the result of
stimulating cellular proliferation, cellular viability of HUVEC-CS
during culture was quantiﬁed. In comparison with non-FMOD con-
trols, there was no signiﬁcant difference in HUVEC-CS cell viability
in 2 and 10 lg/ml FMOD cultivation during the entire experimental
period (Supplementary Fig. 1). Signiﬁcant reduction of HUVEC-CS
viability was observed in long-term (day-9) cultivation with
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Fig. 2. FMOD promoted HUVEC-CS adhesion and spreading in vitro. (A) Adhered
HUVEC-CS cells were calculated after 3 h cultivation. (B) Adhered cells were stained
with antibody against vinculin and Alexa Fluor 488-labeled phalloidin. Nuclei
were stained by DAPI. (C) Area of adhered cells was also calculated after 3 h
cultivation. ⁄signiﬁcant difference; N = 4. Bar = 30 lm.
BA
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Fig. 3. FMOD promoted in vivo angiogenesis. Macroscopic photographs of blood
vessel generation on CAM treated with (A) non-FMOD PBS control and (B) 2.0 mg/
ml FMOD on day-13. Bar = 500 lm.
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was not evidenced at earlier time points (Supplementary Fig. 1).
3.3. FMOD orchestrated HUVEC-CS cell gene expression in favor of
angiogenesis
2 lg/ml FMOD did not notably affect type I or type III collagen
expression in HUVEC-CS cells. However, by increasing the concen-
tration of FMOD to 10 and 50 lg/ml, type I and type III collagen
expression was signiﬁcantly elevated (Supplementary Fig. 2A, B).
FMOD also stimulated HUVEC-CS angiopoietin (Ang)-2 expression
in a dose-dependent manner (Supplementary Fig. 2C). On the other
hand, expression of Tie2, the predominant receptor of Ang-1 and
Ang-2 signals [28], did not respond to FMOD treatment (Supple-
mentary Fig. 2D). Interestingly, high dose (10 and 50 lg/ml) FMOD
slightly inhibited Ang-1 expression in long-term (10 and 15 days)
cultivation (Supplementary Fig. 3A), while the well-known angio-
genesis growth factor vascular endothelial growth factor (VEGF)
expression in HUVEC-CS cells was considerably upregulated by
FMOD administration (Supplementary Fig. 3B).
3.4. FMOD enhanced in vivo angiogenesis
Using the in ovo CAM assay, we further examined the in vivo
pro-angiogenic potential of FMOD. Macroscopic observation
showed that CAMs in the non-FMOD treated group had only a
few slim blood vessels on day-13 (Fig. 3A). On the other hand, a
signiﬁcant increase of blood vessels with large diameters was doc-
umented in CAMs treated with FMOD (Fig. 3B). Therefore, FMOD
also promoted angiogenesis in vivo.4. Discussion
Structurally, FMOD is a member of the small leucine-rich pro-
teoglycan (SLRP) family, which also comprises decorin, biglycan,
and lumican [13]. SLRPs are distributed in the ECM of all tissuesand the thin membranes that envelop all major parenchymal or-
gans such as pericardium, pleura, periosteum, perimysium, and
adventitia of blood vessels [12]. The involvement of decorin and
lumican in angiogenesis has been intensively studied [12]. For
example, lumican inhibits angiogenesis by interfering with inte-
grin a2b1 activity and downregulating proteolytic activity associ-
ated with surface membranes of ECs [29]. Meanwhile, decorin
seems to be pro-angiogenic in some early experimental settings
[12,30], but it inhibits EC migration and TLS formation
in vitro[12,22,31]. Additionally, decorin-deﬁciency markedly in-
creases ﬁbrovascular invasion and enhances the formation of blood
vessels in vivo[32]. Additional studies demonstrated that the anti-
angiogenic activity of decorin relies on blocking angiogenic signals
[12,22,31,33,34], especially during pathological angiogenesis such
as that in malignant vascular tumors [35,36]. It is likely that deco-
rin plays a dual moderator role on angiogenesis.
Unlike decorin and lumican, our present results showed that
FMOD signiﬁcantly stimulated EC TLS formation in vitro as well
as blood vessel generation in vivo. In addition, FMOD-deﬁciency re-
duced blood vessel regeneration in adult rodent cutaneous wounds
[19]. In the aspect of cellular behavior, FMOD remarkably en-
hanced EC cell adhesion, spreading, and actin stress ﬁber forma-
tion. Previous studies already highlighted the importance of
mechanical-tension interactions between ECs and their substrate
to promote TLS formation in vitro[37]. It is possible that FMOD
may be responsible for providing a permissive microenvironment
for EC actin stress ﬁber formation and cell spreading during TLS
organization, since FMOD plays important roles in ECM assembly,
organization, and degradation [12,38,39]. Meanwhile, not only do
SLRPs play structural functions in the ECM of all tissues, but they
are also signaling molecules that regulate intracellular signaling
cascades and determine cell fate [15,40]. Our previous studies have
revealed that FMOD modulates TGF-b expression, distribution, and
bioactivity in an isoform-dependent manner [19,41]. Thus, it is also
possible that FMOD interferes with the activation of integrins or
other cell surface receptors that initiate the formation of actin
stress ﬁbers and adhesion contacts, thus promoting cytoskeletal
reorganization for spreading and TLS formation in vitro. On a
molecular level, in vitro angiogenesis is correlated to ECM protein
expression [9,11,26]. For instance, collagen I initiates quiescent
ECs morphogenesis leading to the formation of TLSs [11,26], while
collagen I and III both contribute to vessel wall stability [9,42]. In
the aspect of signal transduction, we also found that FMOD en-
hanced HUVEC-CS cell collagen I and III expression, which corre-
lates with the increase of TLS network organization. In addition,
the Ang/Tie signaling system is essential for vessel remodeling
and maturation [28]. Ang-1 is predominantly expressed in perivas-
cular cells, and binds to Tie2 receptors resulting in promotion of EC
survival signaling, the maintenance of an endothelial barrier, and a
quiescent vasculature [28]. Expressed by ECs, Ang-2 acts mainly as
534 J. Jian et al. / Biochemical and Biophysical Research Communications 436 (2013) 530–535an antagonist for Tie2 receptor signaling by displacing the more ac-
tive ligand Ang-1 from the receptor [28]. However, Ang-2 also has a
direct pro-angiogenic Tie2-independent role [28]. In this study, we
also showed that FMOD stimulated Ang-2 expression, slightly re-
duced Ang-1 level, but did not affect Tie2 transcription in HU-
VEC-CS cells, which suggests that FMOD mobilized quiescent ECs
for angiogenesis, at least partially, via reducing Ang-1/Ang-2 ratios
which are critical in balancing Tie2-mediated signaling and regu-
lating vascular homeostasis and responsiveness to other angio-
genic cues [28]. Furthermore, FMOD also induced VEGF
expression in HUVEC-CS cells, although ECs are not the main
source of VEGF. Because Ang-2 promotes angiogenesis in the pres-
ence of VEGF [28,43], FMOD thus provides a special network to
mobilize quiescent ECs to undergo angiogenesis. Together, these
ﬁndings strongly suggested that FMOD exhibits pro-angiogenic
properties though multiple pathways.
It is also worthy to note that 50 lg/ml FMOD induced HUVEC-
CS aggregation, sharply increased expression of collagen I, III and
Ang-2, and eventually resulted in calciﬁcation in vitro. These phe-
nomena suggest that excessive FMOD levels will result in EC dys-
function. Actually, FMOD was found to regulate tumor stromal
structure, which is characterized by distorted blood vessels accom-
panied by elevated interstitial ﬂuid pressure [39]. Considering the
fact that massive FMOD expression was found in different malig-
nancies [39,44,45], there seems to be a direct link between tumor
progression and FMOD (and maybe other SLRPs too) [9,46].
In conclusion, we demonstrated that FMOD is capable of pro-
moting angiogenesis in vitro and in vivo. Our ﬁndings indicate
FMOD’s pro-angiogenic properties are due to its powerful orches-
trating of pro- and anti-angiogenic signaling. Our results provide
novel insights into angiogenesis regulation, suggesting a potential
therapeutic application of FMOD in wound healing and cancer
therapy as well as other conditions related to abnormal blood ves-
sel generation.
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